Thiazolidinediones but Not Metformin Directly Inhibit the Steroidogenic Enzymes P450c17 and 3β-Hydroxysteroid Dehydrogenase
Open accessThe DOI matches its Crossref record; 42 of the 42 references it cites were found in a registry or an index.
Abstract
Androgen biosynthesis requires 3beta-hydroxysteroid dehydrogenase type II (3betaHSDII) and the 17alpha-hydroxylase and 17,20-lyase activities of cytochrome P450c17. Thiazolidinedione and biguanide drugs, which are used to increase insulin sensitivity in type 2 diabetes, lower serum androgen concentrations in women with polycystic ovary syndrome. However, it is unclear whether this is secondary to increased insulin sensitivity or to direct effects on steroidogenesis. To investigate potential actions of these drugs on P450c17 and 3betaHSDII, we used "humanized yeast" that express these steroidogenic enzymes in microsomal environments. The biguanide metformin had no effect on either enzyme, whereas the thiazolidinedione troglitazone inhibited 3betaHSDII (K(I) = 25.4 +/- 5.1 microm) and both activities of P450c17 (K(I) for 17alpha-hydroxylase, 8.4 +/- 0.6 microm; K(I) for 17,20-lyase, 5.3 +/- 0.7 microm). The action of troglitazone on P450c17 was competitive, but it was mainly a noncompetitive inhibitor of 3betaHSDII. The thiazolidinediones rosiglitazone and pioglitazone exerted direct but weaker inhibitory effects on both P450c17 and 3betaHSDII. These differential effects of the thiazolidinediones do not correlate with their effects on insulin sensitivity, suggesting that distinct regions of the thiazolidinedione molecule mediate these two actions. Thus, thiazolidinediones inhibit two key enzymes in human androgen synthesis contributing to their androgen-lowering effects, whereas metformin affects androgen synthesis indirectly, probably by lowering circulating insulin concentrations.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures

![FIG. 2 Effect of metformin and troglitazone on the differential activities of human P450c17. A , 17 a -hydroxylase activity. Microsomes prepared from yeast coexpressing human P450c17 and human P450 oxidoreductase were incubated with 1 m M [ 14 C]progesterone ( Prog ) and 0-100 m M metformin ( MET ) and troglitazone ( TRO ). 17 a -Hydroxylase activity was assessed as the conversion rate of [ 14 C]progesterone to 17OHP. B , 17,20-lyase activity. Microsomes coexpressing P450c17 and OR were incubated with 1 m M 17-Preg and 0-100 m M metformin and troglitazone. 17,20-Lyase activity was assessed as the conversion rate of [ 3 H]17 a -hydroxypregnenolone to DHEA. Each data point represents the mean 6 S.D. of triplicate determinations.](https://figures.cochat.ai/paper-figures/4221417a95fd41fd829b22d85a3904cd/thiazolidinediones-but-not-metformin-directly-inhibit-the-steroidogenic-enzymes-figure-2.png)
![FIG. 3 Kinetic analysis of the mode of inhibition of P450c17 activities by troglitazone ( TRO ). Lineweaver-Burk plots of 17 a -hydroxylase activity ( A ) and 17,20-lyase activity ( B ) and Dixon plot of 17 a -hydroxylase activity ( C ) in the absence and presence of troglitazone (0-20 m M) and with 0.5, 1, 2, and 4 m M [ 14 C]progesterone ( Prog ) and 17-Preg for the assessment of 17 a -hydroxylase and 17,20-lyase activity, respectively. Incubations were carried out with yeast microsomes (40 m g of total protein) coexpressing human P450c17 and human P450 oxidoreductase. Each data point represents the mean 6 S.D. of triplicate determinations.](https://figures.cochat.ai/paper-figures/0a2f41b8bc8041eeafe30abc2029b10d/thiazolidinediones-but-not-metformin-directly-inhibit-the-steroidogenic-enzymes-figure-3.png)
![FIG. 4 Inhibition of 17 a -hydroxylase activity by troglitazone ( TRO ) in whole cells ( solid line ) and in yeast microsomes ( dotted line ). COS-1 cells transiently expressing human P450c17 and yeast microsomes expressing both P450c17 and P450 oxidoreductase were incubated with [ 14 C]progesterone ( Prog ), and 17 a -hydroxylase activity was determined as the conversion rate of [ 14 C]progesterone to 17OHP. Each data point represents the mean 6 S.D. of triplicate determinations.](https://figures.cochat.ai/paper-figures/00ca13bafc4b44c9ba9879e6bf50d444/thiazolidinediones-but-not-metformin-directly-inhibit-the-steroidogenic-enzymes-figure-4.png)


![FIG. 6 Kinetic analysis of the mode of inhibition of 3 b HSDII activity by troglitazone ( TRO ). Lineweaver-Burk plot ( A ) and Dixon plot ( B ) of 3 b HSDII activity. Incubations were carried out with yeast microsomes (40 m g total protein) expressing human 3 b HSDII in the absence and presence of troglitazone (0-60 m M) with 1, 5, 10, and 20 m M [ 14 C]pregnenolone ( Preg ). Each data point represents the mean 6 S.D. of triplicate determinations.](https://figures.cochat.ai/paper-figures/3eb67229e31543189611c7633bbcc3df/thiazolidinediones-but-not-metformin-directly-inhibit-the-steroidogenic-enzymes-figure-6.png)
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Lehmann, J. M., Moore, L. B., Smith-Oliver, T. A., Wilkison, W. O., Willson, T. M., & Kliewer, S. A. (1995) · Journal of Biological Chemistry · doi:10.1074/jbc.270.22.12953 · Cited by 3,625
Improved method for high efficiency transformation of intact yeast cells
Gietz, D., Jean, A. S., Woods, R. A., & Schiestl, R. H. (1992) · Nucleic Acids Research · doi:10.1093/nar/20.6.1425 · Cited by 3,261
Insulin Resistance and the Polycystic Ovary Syndrome: Mechanism and Implications for Pathogenesis*
Dunaif, A. (1997) · Endocrine Reviews · doi:10.1210/edrv.18.6.0318 · Cited by 2,458
OWEN, M. R., DORAN, E., & HALESTRAP, A. P. (2000) · Biochemical Journal · doi:10.1042/bj3480607 · Cited by 2,157
Roles of PPARs in health and disease
Kersten, S., Desvergne, B., & Wahli, W. (2000) · Nature · doi:10.1038/35013000 · Cited by 1,956
PPAR-gamma: adipogenic regulator and thiazolidinedione receptor.
Spiegelman, B. M. (1998) · Diabetes · doi:10.2337/diabetes.47.4.507 · Cited by 1,730
Aromatase Cytochrome P450, The Enzyme Responsible for Estrogen Biosynthesis*
SIMPSON, E. R., MAHENDROO, M. S., MEANS, G. D., KILGORE, M. W., HINSHELWOOD, M. M., GRAHAM-LORENCE, S., AMARNEH, B., ITO, Y., FISHER, C. R., MICHAEL, M. D., et al. (1994) · Endocrine Reviews · doi:10.1210/edrv-15-3-342 · Cited by 1,537
El-Mir, M.-Y., Nogueira, V., Fontaine, E., Avéret, N., Rigoulet, M., & Leverve, X. (2000) · Journal of Biological Chemistry · doi:10.1074/jbc.275.1.223 · Cited by 1,399
Molecular biology of steroid hormone synthesis
MILLER, W. L. (1988) · Endocrine Reviews · doi:10.1210/edrv-9-3-295 · Cited by 1,397
Self-citationEfficacy of Metformin in Patients with Non-Insulin-Dependent Diabetes Mellitus
DeFronzo, R. A., & Goodman, A. M. (1995) · New England Journal of Medicine · doi:10.1056/nejm199508313330902 · Cited by 1,368
Research works printed but not linked: 11
- Penning, 1997, Endocr. Rev., 18, 281
- Simpson, 1994, Endocr. Rev., 15, 342
- Lin, 1993, Endocrinology, 132, 2498, 10.1210/endo.132.6.8504753 · doi:10.1210/endo.132.6.8504753 · Paper page
- Dunaif, 1997, Endocr. Rev., 18, 774
- Dunaif, 1996, J. Clin. Endocrinol. Metab., 81, 3299
- Ehrmann, 1997, J. Clin. Endocrinol. Metab., 82, 2108
- Lee, 1999, J. Clin. Endocrinol. Metab., 84, 2104
- Nestler, 1997, J. Clin. Endocrinol. Metab., 82, 4075
- Crave, 1995, J. Clin. Endocrinol. Metab., 80, 2057
- Maeshiba, 1997, Arzneim. Forsch., 47, 29
- Cox, 2000, Drug Metab. Dispos., 28, 772
Cited by
The Molecular Biology, Biochemistry, and Physiology of Human Steroidogenesis and Its Disorders
Miller, W. L., & Auchus, R. J. (2011) · Endocrine Reviews · doi:10.1210/er.2010-0013 · Cited by 2,458
Self-citationDiamanti-Kandarakis, E., & Dunaif, A. (2012) · Endocrine Reviews · doi:10.1210/er.2011-1034 · Cited by 1,947
10.1016/b978-1-4160-2911-3.50026-1
(2000) · CrossRef Listing of Deleted DOIs · doi:10.1016/b978-1-4160-2911-3.50026-1 · Cited by 554
Thiazolidinedione Use and Bone Loss in Older Diabetic Adults
Schwartz, A. V., Sellmeyer, D. E., Vittinghoff, E., Palermo, L., Lecka-Czernik, B., Feingold, K. R., Strotmeyer, E. S., Resnick, H. E., Carbone, L., Beamer, B. A., et al. (2006) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2005-2226 · Cited by 500
“TZDs also decrease testosterone levels in women with polycystic ovary syndrome (24, 25).”
BackgroundPalomba, S., Falbo, A., Zullo, F., & Orio, F. (2009) · Endocrine Reviews · doi:10.1210/er.2008-0030 · Cited by 426
Steroidogenesis in the Fetal Testis and Its Susceptibility to Disruption by Exogenous Compounds
Scott, H. M., Mason, J. I., & Sharpe, R. M. (2009) · Endocrine Reviews · doi:10.1210/er.2009-0016 · Cited by 350
“tively inhibited CYP17 and noncompetitively inhibited 3 -HSD (294), and similar results were obtained with pioglitazone and rosiglitazone using human adrenal NCI-”
ResultHuang, N., Pandey, A. V., Agrawal, V., Reardon, W., Lapunzina, P. D., Mowat, D., Jabs, E. W., Vliet, G. V., Sack, J., Flück, C. E., et al. (2005) · The American Journal of Human Genetics · doi:10.1086/429417 · Cited by 336
“This system was originally developed to assay P450c17 activities: the transfected human POR was abundant and not limiting, and the amount of P450c17 was measured by difference spectra, yielding reproducible measures of P450c17 enzymology (Auchus et al. 1998; Arlt et al. 2001), but the ratio of P450c17”
MethodSelf-citationSex steroids and insulin resistance
LIVINGSTONE, C., & COLLISON, M. (2002) · Clinical Science · doi:10.1042/cs1020151 · Cited by 309
Metabolic and Additional Vascular Effects of Thiazolidinediones
Martens, F. M. A. C., Visseren, F. L. J., Lemay, J., de Koning, E. J. P., & Rabelink, T. J. (2002) · Drugs · doi:10.2165/00003495-200262100-00004 · Cited by 291
Insulin-Lowering Agents in the Management of Polycystic Ovary Syndrome
De Leo, V., la Marca, A., & Petraglia, F. (2003) · Endocrine Reviews · doi:10.1210/er.2002-0015 · Cited by 286
Metformin: Is it a drug for all reasons and diseases?
Triggle, C. R., Mohammed, I., Bshesh, K., Marei, I., Ye, K., Ding, H., MacDonald, R., Hollenberg, M. D., & Hill, M. A. (2022) · Metabolism · doi:10.1016/j.metabol.2022.155223 · Cited by 275
Cutaneous androgen metabolism: basic research and clinical perspectives
Chen, W., Thiboutot, D., & Zouboulis, C. C. (2002) · Journal of Investigative Dermatology · doi:10.1046/j.1523-1747.2002.00613.x · Cited by 273
“Thiazolidinediones was recently shown to inhibit directly the steroidogenic enzymes P450c17 and type 2 3b-HSD (Arlt et al, 2001).”
BackgroundBrettenthaler, N., De Geyter, C., Huber, P. R., & Keller, U. (2004) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2003-031737 · Cited by 247
“Thiazolidinediones may have androgen-lowering effects due to inhibition of P450c17 and 3 -hydroxysteroid dehydrogenase, two key enzymes in human androgen synthesis (37).”
BackgroundDiamanti-Kandarakis, E., Christakou, C. D., Kandaraki, E., & Economou, F. N. (2010) · European Journal of Endocrinology · doi:10.1530/eje-09-0733 · Cited by 247
Metformin has direct effects on human ovarian steroidogenesis
Mansfield, R., Galea, R., Brincat, M., Hole, D., & Mason, H. (2003) · Fertility and Sterility · doi:10.1016/s0015-0282(02)04925-7 · Cited by 237
“It has also been reported that thiazolidinediones inhibited P450c17 and 3 HSD activity in a “humanized” yeast expression system, but that metformin had no effect (33).”
BackgroundGoodarzi, M. O., Carmina, E., & Azziz, R. (2015) · The Journal of Steroid Biochemistry and Molecular Biology · doi:10.1016/j.jsbmb.2014.06.003 · Cited by 188
“steroidogenic enzymes such as P450c17 and 3b-HSD [120].”
BackgroundReview: Role of metformin in the management of polycystic ovary syndrome
Lashen, H. (2010) · Therapeutic Advances in Endocrinology and Metabolism · doi:10.1177/2042018810380215 · Cited by 173
“The effect of metformin on androgen production has been controversial [Arlt et al. 2001; Bailey and Puah, 1986].”
BackgroundGenetics of polycystic ovary syndrome: searching for the way out of the labyrinth
Diamanti-Kandarakis, E., & Piperi, C. (2005) · Human Reproduction Update · doi:10.1093/humupd/dmi025 · Cited by 167
“…favourable action of this hormone to 17α-hydroxylase and to 17,20 lyase (cytochrome P450c17α) and in cytochrome P450scc (Poretsky and Kalin, 1987; Nestler and Strauss, 1991; Bergh et al., 1993; Poretsky, 1994; Nestler and Jakubowicz, 1996, 1997a, 1997b; Poretsky et al., 1999; Arlt et al., 2001).”
Munir, I., Yen, H.-W., Geller, D. H., Torbati, D., Bierden, R. M., Weitsman, S. R., Agarwal, S. K., & Magoffin, D. A. (2004) · Endocrinology · doi:10.1210/en.2003-0329 · Cited by 160
Selective ovary resistance to insulin signaling in women with polycystic ovary syndrome
Wu, X. K., Zhou, S. Y., Liu, J. X., Pöllänen, P., Sallinen, K., Mäkinen, M., & Erkkola, R. U. (2003) · Fertility and Sterility · doi:10.1016/s0015-0282(03)01007-0 · Cited by 162
Use of metformin in polycystic ovary syndrome
Mathur, R., Alexander, C. J., Yano, J., Trivax, B., & Azziz, R. (2008) · American Journal of Obstetrics and Gynecology · doi:10.1016/j.ajog.2008.09.010 · Cited by 180
Effects of chronic administration of PPAR-gamma ligand rosiglitazone in Cushing's disease
Ambrosi, B., Dall’Asta, C., Cannavò, S., Libé, R., Vigo, T., Epaminonda, P., Chiodini, I., Ferrero, S., Trimarchi, F., Arosio, M., et al. (2004) · European Journal of Endocrinology · doi:10.1530/eje.0.1510173 · Cited by 147
“In fact, it was previously demonstrated that PPAR-g agonists inhibit ovarian steroidogenesis (14); in addition, a direct effect of rosiglitazone on the steroidogenic enzymes P450c17 and 3b-hydroxysteroid dehydrogenase was proven by in vitro studies ( 15 ).”
BackgroundPolycystic Ovary Syndrome in Adolescence
Buggs, C., & Rosenfield, R. L. (2005) · Endocrinology and Metabolism Clinics of North America · doi:10.1016/j.ecl.2005.04.005 · Cited by 157
“Both types of drugs promote ovulation and lower androgen levels up to about 20% [128,129], although in current regimens, they have little if any direct effect on steroidogenesis [130,131].”
BackgroundYilmaz, M., Bukan, N., Ayvaz, G., Karakoç, A., Törüner, F., Çakir, N., & Arslan, M. (2005) · Human Reproduction · doi:10.1093/humrep/dei258 · Cited by 138
“Rosiglitazone has also a direct but weaker inhibitory effect on both P450c17 and 3β-Hydroxy steroid dehydrogenase II (3β-OH steroid DH II) than troglitazone (Arlt et al., 2001).”
BackgroundProtein phosphatase 2A and phosphoprotein SET regulate androgen production by P450c17
Pandey, A. V., Mellon, S. H., & Miller, W. L. (2003) · Journal of Biological Chemistry · doi:10.1074/jbc.m209527200 · Cited by 137
Self-citationThe adrenal and polycystic ovary syndrome
Yıldız, B. O., & Azziz, R. (2007) · Reviews in Endocrine and Metabolic Disorders · doi:10.1007/s11154-007-9054-0 · Cited by 149
“It is possible that the effect of thiazolidinediones observed on steroid levels may be the result of direct inhibition of steroid biosynthesis by these drugs [79].”
BackgroundBremer, A. A., & Miller, W. L. (2008) · Fertility and Sterility · doi:10.1016/j.fertnstert.2008.02.091 · Cited by 151
Self-citationEffects of Rosiglitazone in Obese Women with Polycystic Ovary Syndrome and Severe Insulin Resistance
Sepilian, V., & Nagamani, M. (2005) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2004-1376 · Cited by 139
Drug Insight: insulin-sensitizing drugs in the treatment of polycystic ovary syndrome—a reappraisal
Dunaif, A. E. (2008) · Nature Clinical Practice Endocrinology & Metabolism · doi:10.1038/ncpendmet0787 · Cited by 129
“Thiazolidinediones do, however, seem to have direct effects on steroidogenesis that could contribute to these changes”
BackgroundHirsch, A., Hahn, D., Kempná, P., Hofer, G., Nuoffer, J.-M., Mullis, P. E., & Flück, C. E. (2012) · Endocrinology · doi:10.1210/en.2012-1145 · Cited by 109
New and emerging treatments in dermatology: acne
Katsambas, A., & Dessinioti, C. (2008) · Dermatologic Therapy · doi:10.1111/j.1529-8019.2008.00175.x · Cited by 110
“In addition, isofalvonoids such as genistein and daidzein (85), as well as thiazolidinediones (86), have been shown to act as 3 β -HSD inhibitors.”
BackgroundMetformin in Reproductive Biology
Faure, M., Bertoldo, M. J., Khoueiry, R., Bongrani, A., Brion, F., Giulivi, C., Dupont, J., & Froment, P. (2018) · Frontiers in Endocrinology · doi:10.3389/fendo.2018.00675 · Cited by 109
Rautio, K., Tapanainen, J. S., Ruokonen, A., & Morin-Papunen, L. C. (2006) · Human Reproduction · doi:10.1093/humrep/dei505 · Cited by 88
“, 2005; Sepilian and Nagamani, 2005) and/or with the direct effect of these agents on ovarian/adrenal steroidogenesis (Arlt et al., 2001; Guido et al., 2004; SetoYoung et al., 2005).”
BackgroundTroglitazone decreases adrenal androgen levels in women with polycystic ovary syndrome
Azziz, R., Ehrmann, D. A., Legro, R. S., Fereshetian, A. G., O’Keefe, M., & Ghazzi, M. N. (2003) · Fertility and Sterility · doi:10.1016/s0015-0282(02)04914-2 · Cited by 91
Tosca, L., Solnais, P., Ferré, P., Foufelle, F., & Dupont, J. (2006) · Biology of Reproduction · doi:10.1095/biolreprod.106.050831 · Cited by 86
“Indeed, troglitazone inhibits the HSD3B2 activity in microsomes from transformed yeast, whereas metformin does not [30].”
BackgroundSchoppee, P. D., Garmey, J. C., & Veldhuis, J. D. (2002) · Biology of Reproduction · doi:10.1095/biolreprod66.1.190 · Cited by 92
Yılmaz, M., Karakoç, A., Törüner, F. B., Çakır, N., Tıraş, B., Ayvaz, G., & Arslan, M. (2005) · Gynecological Endocrinology · doi:10.1080/09513590500231627 · Cited by 85
“Rosiglitazone has direct but weaker inhibitory effects on both P450c17 (17a-hydroxylase/17,20-lyase) and 3bHSDII (3b-hydroxysteroid dehydrogenase) than troglitazone [42].”
BackgroundGiraldi, F. P., Scaroni, C. M., Arvat, E., Martin, M. D., Giordano, R., Albiger, N. M. E., Leão, A. A. S., Picu, A., Mantero, F., & Cavagnini, F. (2006) · Clinical Endocrinology · doi:10.1111/j.1365-2265.2006.02452.x · Cited by 82
Endocrine and Metabolic Effects of Rosiglitazone in Non-obese Women with Polycystic Ovary Disease
Dereli, D., Dereli, T., Bayraktar, F., Özgen, G., & Yılmaz, C. (2005) · Endocrine Journal · doi:10.1507/endocrj.52.299 · Cited by 92
Betz, M. J., Shapiro, I., Faßnacht, M., Hahner, S., Reincke, M., & Beuschlein, F. (2005) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2004-1267 · Cited by 76
Differential Inhibition of CYP17A1 and CYP21A2 Activities by the P450 Oxidoreductase Mutant A287P
Dhir, V., Ivison, H. E., Krone, N., Shackleton, C. H. L., Doherty, A. J., Stewart, P. M., & Arlt, W. (2007) · Molecular Endocrinology · doi:10.1210/me.2007-0066 · Cited by 78
Self-citationYilmaz, M., Biri, A., Karakoç, A., Törüner, F., Bingöl, B., Çakir, N., Tiras, B., Ayvaz, G., & Arslan, M. (2005) · Journal of Endocrinological Investigation · doi:10.1007/bf03345339 · Cited by 77
Kempná, P., Hofer, G., Mullis, P. E., & Flück, C. E. (2006) · Molecular Pharmacology · doi:10.1124/mol.106.028902 · Cited by 75
“In fact, pioglitazone and other TZDs have been shown to inhibit enzymatic activities of P450c17 and 3 HSDII directly in vitro (Arlt et al., 2001), but this inhibition was observed only at supratherapeutic concentrations of these drugs.”
InfluentialVeldhuis, J. D., Zhang, G., & Garmey, J. C. (2002) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.87.3.1129 · Cited by 73
Aroda, V. R., Ciaraldi, T. P., Burke, P., Mudaliar, S., Clopton, P., Phillips, S., Chang, R. J., & Henry, R. R. (2009) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2008-1133 · Cited by 71
Tee, M. K., & Miller, W. L. (2013) · Journal of Biological Chemistry · doi:10.1074/jbc.m113.460048 · Cited by 75
“Because some planar hydrocarbons having structures unrelated to steroids may act as competitive inhibitors of P450c17 (75), we determined whether the pyridinyl imidazole kinase inhibitors had a direct action on P450c17.”
BackgroundSelf-citationEffects of Thiazolidinediones on Bone Loss and Fracture
Murphy, C. E., & Rodgers, P. T. (2007) · Annals of Pharmacotherapy · doi:10.1345/aph.1k286 · Cited by 64
Hahn, S., Fingerhut, A., Khomtsiv, U., Khomtsiv, L., Tan, S., Quadbeck, B., Herrmann, B. L., Knebel, B., Müller‐Wieland, D., Mann, K., et al. (2005) · Clinical Endocrinology · doi:10.1111/j.1365-2265.2005.02261.x · Cited by 63
Fedorcsák, P., Dale, P. O., Storeng, R., Åbyholm, T., & Tanbo, T. G. (2003) · Gynecological Endocrinology · doi:10.1080/713603249 · Cited by 63
Polycystic ovarian syndrome – prognosis and outcomes
Hart, R. J., & Norman, R. J. (2006) · Best Practice & Research Clinical Obstetrics & Gynaecology · doi:10.1016/j.bpobgyn.2006.04.006 · Cited by 68
Treatment of PCOS in adolescence
Warren-Ulanch, J., & Arslanian, S. A. (2006) · Best Practice & Research Clinical Endocrinology & Metabolism · doi:10.1016/j.beem.2006.02.002 · Cited by 68
Coffler, M. S., Patel, K. S., Dahan, M. H., Yoo, R. Y., Malcom, P. J., & Chang, R. J. (2003) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2003-030745 · Cited by 64
Davies, G. F., McFie, P. J., Khandelwal, R. L., & Roesler, W. J. (2002) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.300.1.72 · Cited by 66
Insulin-sensitizing agents: use in pregnancy and as therapy in polycystic ovary syndrome
Checa, M. Á., Requena, A., Salvador, C., Tur, R., Callejo, J., Espinós, J. J., Fábregues, F., Herrero, J. C., & (Reproductive Endocrinology Interest Group of the Spanish Society of Fertility) (2005) · Human Reproduction Update · doi:10.1093/humupd/dmi015 · Cited by 68
“synthesis indirectly, probably by lowering circulating insulin concentrations (Arlt et al., 2001).”
BackgroundPPAR Gamma: Coordinating Metabolic and Immune Contributions to Female Fertility
Minge, C. E., Robker, R. L., & Norman, R. J. (2008) · PPAR Research · doi:10.1155/2008/243791 · Cited by 60
“As the entire range of leptin and adiponectin effects on ovarian cellular functions, including the outcomes of PPARG activation (including enhancement of insulin sensitivity), are gradually established, it is likely we will find that the improvements to reproductive profiles and ovarian function of…”
BackgroundGuido, M., Romualdi, D., Suriano, R., Giuliani, M., Costantini, B., Apa, R., & Lanzone, A. (2004) · Human Reproduction · doi:10.1093/humrep/deh145 · Cited by 52
“…seems to be able to inhibit androgen synthesis only indirectly, most likely by decreasing insulin circulating levels; by contrast thiazolidinediones also display a direct inhibitory effect on the enzymatic activities of cP450-17a and 3b- hydroxysteroid dehydrogenase type 2 (Arlt et al., 2001).”
BackgroundNutrigenomics: Concepts and Applications to Pharmacogenomics and Clinical Medicine
Kaput, J., Perlina, A., Hatipoğlu, B., Bartholomew, A. M., & Nikolsky, Y. (2007) · Pharmacogenomics · doi:10.2217/14622416.8.4.369 · Cited by 56
The Adrenal Cortex and its Disorders
Miller, W. L. (2009) · Wiley eBooks · doi:10.1002/9781444316728.ch13 · Cited by 51
Self-citationZhou, R., Bruns, C. M., Bird, I. M., Kemnitz, J. W., Goodfriend, T. L., Dumesic, D. A., & Abbott, D. H. (2007) · Reproductive Toxicology · doi:10.1016/j.reprotox.2006.12.009 · Cited by 51
Mehta, R. V., Patel, K. S., Coffler, M. S., Dahan, M. H., Yoo, R. Y., Archer, J. S., Malcom, P. J., & Chang, R. J. (2005) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2004-1040 · Cited by 47
Jensterle, M., Janez, A., Mlinar, B., Marc, J., Prezelj, J., & Pfeifer, M. (2008) · European Journal of Endocrinology · doi:10.1530/eje-07-0857 · Cited by 47
“The information on metformin actions on tissues other than hepatic tissues varies (16, 17, 54 , 55), and the question of direct effects of metformin on ovarian steroidogenesis remains to be resolved.”
BackgroundPPAR‐γ signalling as a key mediator of human hair follicle physiology and pathology
Ramot, Y., Bertolini, M., Boboljova, M., Uchida, Y., & Paus, R. (2019) · Experimental Dermatology · doi:10.1111/exd.14062 · Cited by 49
Insulin resistance and metformin in polycystic ovary syndrome
Ben‐Haroush, A., Yogev, Y., & Fisch, B. (2004) · European Journal of Obstetrics & Gynecology and Reproductive Biology · doi:10.1016/j.ejogrb.2003.11.027 · Cited by 59
“[51] reporting that thiazolidinediones, not metformin, inhibit 3 beta-hydroxysteroid dehydrogenase type II and both activities of P450c17, the key enzymes in human androgen synthesis.”
BackgroundTroglitazone: A Possible Modulator of Ovarian Steroidogenesis
Mitwally, M. F., Witchel, S. F., & Casper, R. F. (2002) · Journal of the Society for Gynecologic Investigation · doi:10.1177/107155760200900308 · Cited by 44
Berberoğlu, Z., Yazıcı, A. C., & Demirağ, N. G. (2010) · Clinical Endocrinology · doi:10.1111/j.1365-2265.2010.03784.x · Cited by 44
Targets to treat metabolic syndrome in polycystic ovary syndrome
Mahalingaiah, S., & Diamanti‐Kandarakis, E. (2015) · Expert Opinion on Therapeutic Targets · doi:10.1517/14728222.2015.1101067 · Cited by 48
Ota, H., Goto, T., Yoshioka, T., & Ohyama, N. (2008) · Fertility and Sterility · doi:10.1016/j.fertnstert.2007.01.117 · Cited by 42
Polycystic Ovary Syndrome and Hyperandrogenic States
Chang, R. J., & Dumesic, D. A. (2019) · Elsevier eBooks · doi:10.1016/b978-0-323-47912-7.00021-4 · Cited by 49
Steroidogenic alterations and adrenal androgen excess in PCOS
Doi, S. A. R., Al-Zaid, M. M., Towers, P. A., Scott, C., & Al-Shoumer, K. A. S. (2006) · Steroids · doi:10.1016/j.steroids.2006.05.005 · Cited by 41
“[75] Arlt W, Auchus RJ, Miller WL.”
BackgroundSimilar causes of various reproductive disorders in early life
Söder, O., Svechnikov, K., Stukenborg, J., & Savchuk, I. (2014) · Asian Journal of Andrology · doi:10.4103/1008-682x.122199 · Cited by 48
Antoine, H. J., Pall, M., Trader, B. C., Chen, Y. I., Azziz, R., & Goodarzi, M. O. (2006) · Fertility and Sterility · doi:10.1016/j.fertnstert.2006.10.006 · Cited by 44
Vierhapper, H., Nowotny, P., & Waldhäusl, W. K. (2003) · Metabolism · doi:10.1053/meta.2003.50028 · Cited by 40
Meal intake similarly reduces circulating concentrations of octanoyl and total ghrelin in humans
Lucidi, P., Murdolo, G., Loreto, C. D., Parlanti, N., Cicco, A. D., Ranchelli, A., Fatone, C., Taglioni, C., Fanelli, C. G., Santeusanio, F., et al. (2004) · Journal of Endocrinological Investigation · doi:10.1007/bf03345282 · Cited by 50
Auchus, R. J., Sampath Kumar, A., Andrew Boswell, C., Gupta, M. K., Bruce, K., Rath, N. P., & Covey, D. F. (2003) · Archives of Biochemistry and Biophysics · doi:10.1016/s0003-9861(02)00491-5 · Cited by 39
Self-citationPolycystic ovary syndrome in adolescents: is there an epidemic?
Arslanian, S. A., & Witchel, S. F. (2002) · Current Opinion in Endocrinology & Diabetes · doi:10.1097/00060793-200202000-00006 · Cited by 45
Pharmacological Approaches to Controlling Cardiometabolic Risk in Women with PCOS
Cignarella, A., Mioni, R., Sabbadin, C., Dassie, F., Parolin, M., Vettor, R., Barbot, M., & Scaroni, C. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21249554 · Cited by 36
Insulin-Lowering Agents Inhibit Synthesis of Testosterone in Ovaries of DHEA-Induced PCOS Rats
Misugi, T., Ozaki, K., Beltagy, K. E., Tokuyama, O., Honda, K.-I., & Ishiko, O. (2006) · Gynecologic and Obstetric Investigation · doi:10.1159/000091496 · Cited by 39
“In this study, we investigated if insulin-lowering agents have some effect on ovarian tissue in DHEA-induced PCOS model rats. The concentrations of plasma testosterone were 7.4 times higher in rats of the DHEA group than the control rats, but significantly lower in the DHEA plus metformin, pioglitazone or troglitazone…”
BackgroundInfluentialSathyapalan, T., Smith, K. A., Coady, A., Kilpatrick, E. S., & Atkin, S. L. (2011) · Annals of Clinical Biochemistry International Journal of Laboratory Medicine · doi:10.1258/acb.2011.011071 · Cited by 38
Styne, D. M., & Grumbach, M. M. (2011) · Elsevier eBooks · doi:10.1016/b978-1-4377-0324-5.00025-0 · Cited by 42
Diabetes and fracture healing: the skeletal effects of diabetic drugs
Simpson, C., Calori, G. M., & Giannoudis, P. V. (2011) · Expert Opinion on Drug Safety · doi:10.1517/14740338.2012.639359 · Cited by 34
Gómez, F. E., Miyazaki, M., Kim, Y., Marwah, P., Lardy, H. A., Ntambi, J. M., & Fox, B. G. (2002) · Biochemistry · doi:10.1021/bi012177r · Cited by 33
Garmes, H. M., Tambascia, M. A., & Zantut‐Wittmann, D. E. (2005) · Gynecological Endocrinology · doi:10.1080/09513590500430575 · Cited by 31
“Arlt and co-workers have shown that rosiglitazone and pioglitazone directly inhibit 3b-hydroxysteroid dehydrogenase and cytochrome P450c17, essential enzymes in androgen synthesis [39].”
BackgroundGlycemic Control with Thiazolidinedione Is Associated with Fracture of T2DM Patients
Chen, H., Horng, M.-H., Yeh, S.-Y., Lin, I., Yeh, C., Muo, C., Sung, F., & Kao, C. (2015) · PLoS ONE · doi:10.1371/journal.pone.0135530 · Cited by 28
“Another mechanism whereby TZDs affect fracture healing time is through their inhibitory effects on estrogen and androgen biosynthesis [13].”
BackgroundInfluentialSridhar, S., Walia, R., Sachdeva, N. K., & Bhansali, A. K. (2012) · Clinical Endocrinology · doi:10.1111/j.1365-2265.2012.04510.x · Cited by 29
Silva, R. D. C., Pardini, D., & Kater, C. E. (2006) · Arquivos Brasileiros de Endocrinologia & Metabologia · doi:10.1590/s0004-27302006000200014 · Cited by 75
Does metformin induce ovulation in normoandrogenic anovulatory women?
Carmina, E., & Løbo, R. A. (2004) · American Journal of Obstetrics and Gynecology · doi:10.1016/j.ajog.2004.05.030 · Cited by 31
Romualdi, D., Giuliani, M., Draisci, G., Costantini, B., Cristello, F., Lanzone, A., & Guido, M. (2007) · Fertility and Sterility · doi:10.1016/j.fertnstert.2006.11.076 · Cited by 29
Valsamakis, G., Lois, K., Kumar, S., & Mastorakos, G. P. (2013) · HORMONES · doi:10.1007/bf03401302 · Cited by 30
Impact of androgens on fertility – physiological, clinical and therapeutic aspects
Hugues, J., & Cédrin‐Durnerin, I. (2005) · Reproductive BioMedicine Online · doi:10.1016/s1472-6483(10)61165-0 · Cited by 30
Polycystic Ovary Syndrome in Adolescence
Baumann, E. E., & Rosenfield, R. L. (2002) · The Endocrinologist · doi:10.1097/00019616-200207000-00011 · Cited by 30
Rak, A., & Karpeta, A. (2014) · Theriogenology · doi:10.1016/j.theriogenology.2014.02.016 · Cited by 29
Jensterle, M., Goričar, K., & Janež, A. (2017) · Endocrine Research · doi:10.1080/07435800.2017.1294602 · Cited by 28
“In in vitro studies it was suggested that PIOmight reduce the PCOS associated P450c17 up-regulation either by direct effect on ovaries or indirectly via the reduction of circulating insulin (31,32,33).”
BackgroundFlück, C. E., Yaworsky, D. C., & Miller, W. L. (2005) · Epilepsia · doi:10.1111/j.0013-9580.2005.38404.x · Cited by 25
“Because the Km and Vmax values of 3βHSDII are equivalent for the three principal substrates (Preg, 17OHPreg, and DHEA), the conversion of Preg to Prog reflects the conversion of 17OHPreg to 17OHProg or the conversion of DHEA to Andro (6).”
BackgroundMethodSelf-citationCannavò, S., Ambrosi, B., Chiodini, I., Vigo, T., Russo, A., Milici, C., Barbetta, L., Dall’Asta, C., Adda, G., & Arosio, M. (2004) · Journal of Endocrinological Investigation · doi:10.1007/bf03345281 · Cited by 26
Activation of PPAR-γ reduces HPA axis activity in diabetic rats by up-regulating PI3K expression
Torres, R. C., Magalhães, N. S., Silva, P., Martins, M. A., & Carvalho, V. F. (2016) · Experimental and Molecular Pathology · doi:10.1016/j.yexmp.2016.10.002 · Cited by 22
Jensterle, M., Janež, A., Vrtovec, B., Meden‐Vrtovec, H., Pfeifer, M., Preželj, J., & Kocjan, T. (2007) · Croatian Medical Journal · doi:10.3325/cmj.2007.6.864 · Cited by 22
Role of AMP-Activated Protein Kinase on Steroid Hormone Biosynthesis in Adrenal NCI-H295R Cells
Hirsch, A., Hahn, D., Kempná, P., Hofer, G., Mullis, P. E., Nuoffer, J., & Flück, C. E. (2012) · PLoS ONE · doi:10.1371/journal.pone.0030956 · Cited by 26
“Steroids were extracted from medium as previously described [19] and separated on thin layer chromatography (TLC) plates (Macherey-Nagel, Düren, Germany).”
MethodDangudubiyyam, S. V., Mishra, J. S., & Kumar, S. (2023) · Reproductive Toxicology · doi:10.1016/j.reprotox.2023.108390 · Cited by 22
Tatone, C., Benedetti, E., Vitti, M., Emidio, G. D., Ciriminna, R., Vento, M. E., Cela, V., Borzì, P., Carta, G., Lispi, M., et al. (2015) · Journal of Cellular Physiology · doi:10.1002/jcp.25182 · Cited by 19
“This PPAR is known to inhibit progesterone production in in vitro basal and gonadotropins stimulated cultured human GCs by negatively affecting the activity of 3bHSD II (Arlt et al., 2001).”
BackgroundResultArlt, W., Neogi, P., Gross, C., & Miller, W. L. (2004) · Journal of Molecular Endocrinology · doi:10.1677/jme.0.0320425 · Cited by 22
“This is seen with the differences between M3 and M5 compared with M2 and M4, and is consistent with the previously observed differences among tro-, pio- and rosiglitazone (Arlt et al. 2001), which contain the same TZD core but different side groups.”
BackgroundMethodResultSelf-citation
Metadata
- Authors
- Arlt, W., Auchus, R. J., & Miller, W. L.
- Affiliations
- University of California, San Francisco (US)
- The University of Texas Southwestern Medical Center (US)
- Corresponding author
- Miller, Walter L.
- Venue
- Journal of Biological Chemistry
- Publisher
- Elsevier BV
- Published
- 2001-05
- Volume
- 276
- Issue
- 20
- Pages
- 16767-16771
- ISSN
- 0021-9258 (ISSN-L)
- OpenAlex
- W2050353370
- Semantic Scholar
- 882bbddf93d24e3507b22bb163aad3ac5fa2f1ce
- Cited by
- 157
- References
- 42
- Citations by year
- 2026: 1 · 2025: 2 · 2024: 1 · 2023: 3 · 2022: 7 · 2021: 2 · 2020: 1 · 2019: 3 · 2018: 1 · 2017: 3 · 2016: 1 · 2015: 5 · 2014: 3 · 2013: 7 · 2012: 7
- FWCI
- 12.52
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Licence
- cc-by
- www.elsevier.com/tdm/userlicense/1.0/ (tdm)
- creativecommons.org/licenses/by/4.0/ (vor, 7088 d)
- Locations
- Journal of Biological Chemistry (publishedVersion, cc-by)
- PubMed (publishedVersion)
- University of Birmingham Research Portal (University of Birmingham) (submittedVersion)
- Spiral (Imperial College London) (submittedVersion, cc-by)
- Funders
- Deutsche Forschungsgemeinschaft
- National Institutes of Health (5k08dk002387-06)
- National Institute of Diabetes and Digestive and Kidney Diseases (K08 DK 02387, R01DK037922, R01DK37922)
- Eunice Kennedy Shriver National Institute of Child Health and Human Development (U54-HD34449, U54HD034449)
- Topics
- Health Sciences › Medicine › Reproductive Medicine › Ovarian function and disorders
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Adrenal Hormones and Disorders
- Life Sciences › Pharmacology, Toxicology and Pharmaceutics › Pharmacology › Pharmacogenetics and Drug Metabolism
- Keywords
- thiazolidinediones, metformin, P450c17, steroidogenesis, androgen production, troglitazone, rosiglitazone, pioglitazone, polycystic ovary syndrome, enzyme inhibition, insulin sensitivity, type 2 diabetes
- MeSH terms
- Pioglitazone, Troglitazone, Biguanides, Chromans, Cloning, Molecular, Humans, Kinetics, Metformin, Recombinant Proteins, Saccharomyces cerevisiae, Steroid Hydroxylases, Steroid 17-alpha-Hydroxylase, Thiazoles, 3-Hydroxysteroid Dehydrogenases, Thiazolidinediones
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.